


PHARMACEUTICAL 2020

uniQure N.V. Rank 110 of 362







PHARMACEUTICAL 2020

uniQure N.V. Rank 110 of 362



The relative strengths and weaknesses of uniQure N.V. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of uniQure N.V. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 155% points. The greatest weakness of uniQure N.V. is the variable Revenues, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is -51%, being 251% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	384,206
Cost of Goods Sold	0
Intangible Assets	5,923
Liabilities, Current	31,630
Liabilities, Non-Current	93,942
Other Assets	29,730
Other Compr. Net Income	570
Other Expenses	5,838
Other Liabilities	0
Other Net Income	749
Property and Equipment	28,771
Research and Development	94,737
Revenues	9,169
Selling, General and Administrative Expense	33,544

Output Variable	Value in 1000 USD
Assets	448,630
Liabilities	125,572
Expenses	134,119
Stockholders Equity	323,058
Net Income	-124,201
Comprehensive Net Income	-123,916
Economic Capital Ratio	-51%

